4.3 Article

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences

Journal

CURRENT MEDICAL RESEARCH AND OPINION
Volume 25, Issue 2, Pages 375-383

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1185/03007990802634119

Keywords

Health-related quality of life; Immune thrombocytopenic purpura; ITP-PAQ; Minimal important differences; Questionnaire

Funding

  1. Amgen, Inc,
  2. Thousand Oaks, CA, USA

Ask authors/readers for more resources

Objective: Interpretation of data from health-related quality of life (HRQoL) questionnaires can be enhanced with the availability of minimally important difference ( MID) estimates. This information will aid clinicians in interpreting HRQoL differences within patients over time and between treatment groups. The Immune Thrombocytopenic Purpura (ITP)-Patient Assessment Questionnaire (PAQ) is the only comprehensive HRQoL questionnaire available for adults with ITP. Research design and methods: Forty centers from within the US and Europe enrolled ITP patients into one of two multicenter, randomized, placebo-controlled, double-blind, 6-month, phase III clinical trials of romiplostim. Patients enrolled in these studies self-administered the ITP-PAQ and two items assessing global change (anchors) at baseline and weeks 4, 12, and 24. Using data from the ITP-PAQ and these two anchors, an anchor-based estimate was computed and combined with the standard error of measurement and standard deviation to compute a distribution-based estimate in order to provide an MID range for each of the 11 scales of the ITP-PAQ. Results: A total of 125 patients participated in these clinical trials and provided data for use in these analyses. Combining results from anchor-and distribution-based approaches, MID values were computed for 9 of the 11 scales. MIDs ranged from 8 to 12 points for Symptoms, Bother, Psychological, Overall QOL, Social Activity, Menstrual Symptoms, and Fertility, while the range was 10 to 15 points for the Fatigue and Activity scales of the ITP-PAQ. These estimates, while slightly higher than other published MID estimates, were consistent with moderate effect sizes. Conclusions: These MID estimates will serve as a useful tool to researchers and clinicians using the ITP-PAQ, providing guidance for interpretation of baseline scores as well as changes in ITP-PAQ scores over time. Additional work should be done to finalize these initial estimates using more appropriate anchors that correlate more highly with the ITP-PAQ scales.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available